search
Back to results

THIRST Alert Trial (THIRST)

Primary Purpose

Fluid Overload, Congestive Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Fluid restriction
Free fluids
Sponsored by
University College, London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fluid Overload focused on measuring Electronic health record, Comparative effectiveness research, Pragmatic trial, Learning health systems, Heart Failure, Treatable trait

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Prescribed IV furosemide during the first 48h of their admission as a regular prescription rather than a one-off dose. Assessed as being suitable for inclusion in the trial by the responsible clinical team i.e., fluid restriction deemed to be in equipoise. Exclusion Criteria: On a surgical, obstetric or critical care ward environment Patients who opt out of study

Sites / Locations

  • University College HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Alert recommending oral fluid restriction

Alert recommending no oral fluid restriction

Arm Description

The alert will suggest to the treating clinician to fluid restrict the patient to 1L of oral fluid per day

The alert will suggest to the treating clinician to continue without any oral fluid restriction

Outcomes

Primary Outcome Measures

Number of patients recruited into the trial
The number of patients in which the usual care team thought there was equipoise for oral fluid restriction
Difference in oral fluid intake between intervention and control arms
Difference in documented oral intake (ml)

Secondary Outcome Measures

Adherence to randomised alert recommendation
Proportion of alerts actioned with corresponding clinical documentation
Proportion of alerts with clinical orders for nursing staff
Corresponding documentation of nursing receipt of treatment allocation
Oral fluid intake
Documented oral fluid intake (ml)
Net fluid balance
Documented overall fluid balance (ml)
Weight change after randomisation
Weight (kg)
Length of stay
Number of Days
Frequency of blood test measurements of renal function
Number of times blood tests are measured
Prescription of Diuretic medications
Dose and duration of intravenous and oral diuretics
Daily change in creatinine
48 hours after randomisation
Patient reported outcome measure
Visual analog scale (1-10) of wellbeing, thirst perception and breathlessness

Full Information

First Posted
April 26, 2023
Last Updated
September 25, 2023
Sponsor
University College, London
Collaborators
University College London Hospitals (UCLH) NHS Foundation Trust, National Institute for Health and Care Research (NIHR) UCLH Biomedical Research Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT05869656
Brief Title
THIRST Alert Trial
Acronym
THIRST
Official Title
THIRST Alert Trial - a Randomised Controlled Trial Within the Electronic Health Record of an Interruptive Alert Displaying a Fluid Restriction Suggestion in Patients With the Treatable Trait of Congestion
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 3, 2023 (Actual)
Primary Completion Date
November 4, 2023 (Anticipated)
Study Completion Date
December 4, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
University College London Hospitals (UCLH) NHS Foundation Trust, National Institute for Health and Care Research (NIHR) UCLH Biomedical Research Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this feasibility study is to determine whether an alert embedded within the electronic health record (EHR) causes clinicians to enrol patients into a randomised controlled trial (RCT) comparing oral fluid restriction versus no restriction in patients admitted to hospital with fluid overload. One of the main causes of fluid overload is heart failure where there is a lack of strong evidence to support the effectiveness of oral fluid restriction in the acute setting. This causes significant variation in clinical practice where decisions on whether or not to impose a restriction in oral fluid intake is based on the preference of the treating clinician rather than robust evidence from research. THIRST Alert is a pragmatic randomised controlled trial (RCT), embedded in the EHR, which seeks to determine whether a computerised alert for the clinical team can change clinician behaviour during routine NHS care at University College London Hospitals NHS Foundation Trust (UCLH). Patients with suspected fluid overload will be identified based on the prescription of intravenous furosemide, a medication used to stimulate diuresis (increased urine output) to remove excess fluid. A repeat prescription of intravenous furosemide within the first 48 hours of an unplanned admission will trigger the alert. A clinician from the treating team will then be asked to consider enrolling the patient into the RCT if they judge that oral fluid restriction might be beneficial but they have uncertainty about this (clinical equipoise). Enrolled patients will be randomised to either oral fluid restriction of 1 litre per day or no fluid restriction. This will then be actioned through documenting as part of the clinical plan in the patients record and then communicated to the patient and the rest of the clinical team, including nursing staff. The study will record the number of patients recruited into the trial and the effect of the alert on enrolled patients' subsequent oral fluid intake. There are no additional tests or follow up for patients and the trial finishes on discharge from the study site. All trial outcomes will use data collected from routine care and the study is supported by the UCLH Biomedical Research Centre, funded by NIHR.
Detailed Description
Trial Design: A single centre, pragmatic, parallel group randomised controlled trial and feasibility study. The study will be conducted entirely within University College Hospital, at University College London Hospitals NHS Foundation Trust. Research Hypothesis: Clinician-facing alerts, delivered through the electronic health records system, provide a feasible method of enrolling patients into pragmatic trials evaluating the effectiveness of routine treatments Clinical Research question: In hospitalised patients with fluid overload, does an automated clinician-facing computerised decision support system (CDSS) alert recommendation for either oral fluid restriction (to 1L per day) or no-fluid restriction (continue with free fluids) result in a change in clinical behaviour and change in the oral fluid intake of enrolled patients? Study participants: The study population will be patients treated for suspected fluid overload with a regular prescription of intravenous (IV) furosemide within 48 hours of an unplanned hospital admission. For staff participants, any clinician with prescribing rights for IV furosemide may be exposed to the CDSS alert. For subsequent medical staff, nursing staff and other allied health professionals, patient enrolment into the trial and their treatment allocation status will be communicated through both EHR and clinical processes that are embedded within routine care, including verbal and non-digital patient handover. Summary of Interventions: This study will evaluate the effect of a Best practice advisory (BPA) interruptive alert that is embedded within the electronic health record (EHR) used at the study site. The first BPA will ask the treating clinician whether they judge randomisation to either oral fluid restriction or no restriction is appropriate - if yes is selected, randomised allocation to one of two subsequent alerts will occur at the point of care. This intervention will be tested in silico prior to deployment to the live EHR. Ethics: This study protocol was approved by the London Riverside Research Ethics Committee (Ref: 22/LO/0889) and sponsored by University College London (Ref: 151938).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fluid Overload, Congestive Heart Failure
Keywords
Electronic health record, Comparative effectiveness research, Pragmatic trial, Learning health systems, Heart Failure, Treatable trait

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Feasibility RCT with an alert intervention that is clinician facing
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Alert recommending oral fluid restriction
Arm Type
Experimental
Arm Description
The alert will suggest to the treating clinician to fluid restrict the patient to 1L of oral fluid per day
Arm Title
Alert recommending no oral fluid restriction
Arm Type
Active Comparator
Arm Description
The alert will suggest to the treating clinician to continue without any oral fluid restriction
Intervention Type
Behavioral
Intervention Name(s)
Fluid restriction
Intervention Description
Oral fluid restriction of 1000ml per day
Intervention Type
Behavioral
Intervention Name(s)
Free fluids
Intervention Description
Continue care without any oral fluid restriction
Primary Outcome Measure Information:
Title
Number of patients recruited into the trial
Description
The number of patients in which the usual care team thought there was equipoise for oral fluid restriction
Time Frame
3 months
Title
Difference in oral fluid intake between intervention and control arms
Description
Difference in documented oral intake (ml)
Time Frame
48 hours after randomisation
Secondary Outcome Measure Information:
Title
Adherence to randomised alert recommendation
Description
Proportion of alerts actioned with corresponding clinical documentation
Time Frame
During trial recruitment window (up to day 2)
Title
Proportion of alerts with clinical orders for nursing staff
Description
Corresponding documentation of nursing receipt of treatment allocation
Time Frame
During trial recruitment window (up to day 2)
Title
Oral fluid intake
Description
Documented oral fluid intake (ml)
Time Frame
From date of randomisation until date of hospital discharge, assessed up to 120 days after trial start date
Title
Net fluid balance
Description
Documented overall fluid balance (ml)
Time Frame
From date of randomisation until date of hospital discharge, assessed up to 120 days after trial start date
Title
Weight change after randomisation
Description
Weight (kg)
Time Frame
48 hours after randomisation
Title
Length of stay
Description
Number of Days
Time Frame
From day of admission to day of discharge, assessed up to 120 days after trial start date
Title
Frequency of blood test measurements of renal function
Description
Number of times blood tests are measured
Time Frame
From date of randomisation until date of hospital discharge, assessed up to 120 days after trial start date
Title
Prescription of Diuretic medications
Description
Dose and duration of intravenous and oral diuretics
Time Frame
From date of randomisation until date of hospital discharge, assessed up to 120 days after trial start date
Title
Daily change in creatinine
Description
48 hours after randomisation
Time Frame
From 48 hours after randomisation until date of hospital discharge, assessed up to 120 days after trial start date
Title
Patient reported outcome measure
Description
Visual analog scale (1-10) of wellbeing, thirst perception and breathlessness
Time Frame
From date of randomisation until date of hospital discharge, assessed up to 120 days after trial start date

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Prescribed IV furosemide during the first 48h of their admission as a regular prescription rather than a one-off dose. Assessed as being suitable for inclusion in the trial by the responsible clinical team i.e., fluid restriction deemed to be in equipoise. Exclusion Criteria: On a surgical, obstetric or critical care ward environment Patients who opt out of study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yang Chen, BMBCh, MSc
Phone
020 3447 8066
Email
yang.a.chen@ucl.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Tom Lumbers, MBBChir, PhD
Phone
020 3447 8066
Email
t.lumbers@ucl.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yang Chen, BMBCh, MSc
Organizational Affiliation
UCL
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tom Lumbers, MBBChir, PhD
Organizational Affiliation
UCL
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anoop D Shah, MBBS, PhD
Organizational Affiliation
UCL
Official's Role
Principal Investigator
Facility Information:
Facility Name
University College Hospital
City
London
ZIP/Postal Code
NW1 2BU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yang Chen, BMBCh
Email
yang.a.chen@ucl.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

THIRST Alert Trial

We'll reach out to this number within 24 hrs